Advertisement

Influence of Hexadecylphosphocholine (Miltefosine) on Cytokine Synthesis and Biological Responses

  • T. Klenner
  • T. Beckers
  • K. Nooter
  • H. Holtmann
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 416)

Abstract

Hexadecylphosphocholine, INN: Miltefosine (Figure 1), the lead compound of the alkylphosphocholines, has shown its antineoplastic activity in various in-vitro and in-vivo tumor models (Hilgard et al. 1993). After oral administration to patients miltefosine induced a remarkable leucocytosis (Pronk et al. 1994). This suggested a stimulatory effect of the compound on the hematopoietic system. To investigate this phenomenon, mouse and rat bone marrow was stimulated with either recombinant mouse/rat IL-3 or mouse GM-CSF with or without the addition of miltefosine. Additionally, Northern blot analysis was performed on human myeloid leukemic cell lines for the IL-3 and GM-CSF receptor genes and for TNFα mRNA on peripheral blood cells stimulated with concanavalin A (Con A) or lipopolysaccharid (LPS) when they were exposed to Miltefosine.

Keywords

Northern Blot Analysis Cytokine Synthesis Colony Form Unit Assay eDNA Probe Human Myeloid Leukemic Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baier JE, Brauckmann-Berger JM, Neumann HA (1995) Modulatorische Eigenschaft des Alkyllysophospholipids Ilmofosin auf Zytokine. Tumordiagn. u. Ther. 16, 88–93Google Scholar
  2. Beckers T, Voegeli R, Hilgard P (1994) Molecular and cellular effects of Hexadecylphosphocholine (Miltefosine) in human myeloid leukemic cell lines. Eur. J. Cancer 30A (14), 2143–2150CrossRefGoogle Scholar
  3. Berger MR, Yanapirut P, Reinhardt M, Klenner T, Scherf HR, Schmeiser HH, Eibl H (1992) Antitumor activity of Alkylphosphocholines and analogues in methylnitrosourea-induced rat mammary carcinomas. In: Eibl H, Hilgard P, Unger C (eds): Alkylphosphocholines: New drugs in Cancer Therapy. Prog Exp Tumor Res. Basel, Karger, Vol. 34, 98–115Google Scholar
  4. Harlemann J (1994) Tumor differentiation in-vivo with Miltefosine. In: Drugs of Today, Clinical aspects of milte- fosine and ist topical formulation Miltex® Ed: Hilgard P, Engel J, Vol. 30, Suppl. B, 43–46Google Scholar
  5. Hilgard P, Klenner T, Stekar J, Unger C (1993) Alkylphosphocholines: A new class of membrane-active anticancer agents. Cancer Chemother Pharmacol 32, 90–95Google Scholar
  6. Holtmann H, Hahn T, Wallach D (1988) Immunobiol. 177, 7–22CrossRefGoogle Scholar
  7. Kitamura T, Sato N, Arai K, Miyajima A. Expression cloning of the human IL-3 receptor cDNA reveals a shared ß-subunit for the human IL-3 and GM-CSF receptors. Cell 1991, 66, 1165–1174PubMedCrossRefGoogle Scholar
  8. Nooter K, Stoter G, Verweij J (1994) Induction of hematopoietic differentiation by the alkylphosphocholine Miltefosine. In: Drugs of Today, Clinical aspects of miltefosine and ist topical formulation Miltex® Ed: Hilgard P, Engel J. Vol. 30, Suppl. B, 31–42Google Scholar
  9. Pronk LC, Planting ASTh, Oosterom R, Drogendijk TE, Stoter G, Verweij J (1994) Increases in leucocyte and platelet counts induced by the alkylphospholipid hexadecylphosphocholine. Eur. J. Cancer, 30A (7), 1019–22CrossRefGoogle Scholar
  10. Überall F, Oberhuber H, Maly K, Zaknun J, Demuth L, Grunicke HH (1991) Hexadecylphosphocholine inhibits inositol phosphate formation and proteinkinase C activity. Cancer Res. 51, 807–812PubMedGoogle Scholar
  11. Winzen R, Wallach D, Kemper O, Resch K, Holtmann H (1993) J. Immunol. 150, 4346–4353PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • T. Klenner
    • 1
  • T. Beckers
    • 1
  • K. Nooter
    • 2
  • H. Holtmann
    • 3
  1. 1.ASTA Medica AGFrankfurt am MainGermany
  2. 2.Department of Medical OncologyUniversity Hospital RotterdamRotterdamThe Netherlands
  3. 3.Institute for Molecular PharmacologyMedical SchoolHannoverGermany

Personalised recommendations